Comparative pharmacology of H1 antihistamines: clinical relevance (Q35041029)

6 August 2017

1 reference

title

Comparative pharmacology of H1 antihistamines: clinical relevance (English)

1 reference

6 August 2017

1 reference

1 reference

1

F Estelle R Simons

1 reference

PubMed ID

12517581

6 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

American Journal of Medicine

6 August 2017

1 reference

6 August 2017

113 Suppl 9A

1 reference

6 August 2017

38S-46S

1 reference

Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

The pharmacology and use of H1-receptor-antagonist drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Clinical pharmacology of H1-antihistamines in the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Ebastine: an update of its use in allergic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

The systemic safety of fexofenadine HCl.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

The clinical pharmacology of fexofenadine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Quantitation of H1-receptor antagonists in skin and serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

Skin concentrations of H1-receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901436-5

10.1016/S0002-9343(02)01436-5

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12517581